USA The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion…
Global The Alliance for Regenerative Medicine (ARM) brands itself as the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. ARM’s latest sector snapshot details the cell and gene therapy approvals list for 2022, as well as the number of…
Global The world’s top 10 medical technology companies for 2022 according to Medical Product Outsourcing (MPO). Abbott leads the way, followed by Medtronic, J&J, and Siemens Healthineers. Recent PharmaBoardroom interviews with some of these companies’ leading executives include Hugo F. Villegas, SVP & President, Canada & Latin America at Medtronic, Eman…
Global The top 20 pharmaceutical companies in the world for the past year, according to Pharmaceutical Executive’s latest annual rankings. Pfizer holds sway at the top of the leaderboard, with its BioNTech-partnered COVID-19 vaccine Comirnaty still generating an incredible USD 37.8 billion in 2022 and its COVID-19 antiviral Paxlovid adding a…
USA An up-to-date list of the US FDA’s Center for Biologics Evaluation & Research (CBER)’s biological license application approvals for 2022. There were nine such approvals in 2022, down from 13 in 2021. For the list of non-biological approvals from the FDA’s Center for Drug Evaluation & Research (CDER), click here.…
USA A comprehensive list of the US FDA’s Center for Drug Evaluation & Research (CDER)’s new drug therapy approvals for 2022. CDER approved 37 new drugs in 2022, down from 50 in 2021, either as new molecular entities (NMEs) under New Drug Applications (NDAs), or as new therapeutic biologics under Biologics…
USA A comprehensive list of the US FDA’s Center for Drug Evaluation & Research (CDER)’s new drug therapy approvals for 2021. CDER approved 50 new drugs in 2021, down from 53 in 2020, either as new molecular entities (NMEs) under New Drug Applications (NDAs), or as new therapeutic biologics under Biologics…
USA In 2020, the US FDA’s Center for Drug Evaluation & Research (CDER) approved 53 novel drugs, up from 48 in 2019, across a range of therapeutic areas, including the first treatments for COVID-19 patients. The FDA’s Center for Biologics Evaluation & Research (CBER) is charged with approving new biologic…
USA In a recent article for PharmaBoardroom, Objective Capital’s David Crean took a look at the state of US innovation today and its long term sustainability. See below for data on the share of US executives who see innovation as a top priority post-COVID, Global Public Equity Issuance for the Biopharmaceutical…
USA In recent years the US has seen an overall decease in cancer deaths thanks to innovative medicines and treatments. However, much work remains to be done in targeting and eliminating cancers. Below we highlight data for cancer deaths and cases in the US per male and female populations. …
Cell & Gene Therapy A full list of the cell and gene therapy products approved by the US FDA. Made with Visme Infographic Maker
India The US generics market stood at USD 69 billion in 2018 and is expected to grow to USD 86 billion by 2022. Made with Visme Infographic Maker Abbreviated New Drug Applications (ANDAs), whereby a company seeks authorisation from the US FDA for a generic copy of a previously approved…
See our Cookie Privacy Policy Here